Researchers identify proteins fueling rare childhood leukemia, revealing new treatment strategy
· Medical Xpressedited by Lisa Lock, reviewed by Andrew Zinin
Lisa Lock
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway. The findings, published in the journal Blood, open the door to more effective treatment options for this rare and aggressive childhood blood cancer, especially for high-risk pediatric patients who currently face limited options.
According to the National Cancer Institute, JMML accounts for about one to two cases per 1 million people. Bone marrow transplants are the most common treatment. However, certain variants cause immense inflammation, and current options are often ineffective.
In the study, scientists identified a specific set of three inflammatory proteins that not only fuel the leukemia's growth but also weaken the body's immune response by exhausting cancer-fighting T cells and expanding immune-suppressive cells. Using mouse models and human patient samples, they found that blocking this inflammatory chain reaction slowed the cancer and supported the immune system.
"We showed that blocking this inflammatory pathway reduced leukemia burden, restored immune function, decreased abnormal myeloid cell growth and significantly improved survival," said Santhosh K. Pasupuleti, Ph.D., assistant research professor of pediatrics at the IU School of Medicine and first and co-corresponding author of the study.
The researchers also discovered that existing medications—such as celecoxib, an FDA-approved anti-inflammatory, and secukinumab, an anti-IL-17A antibody used to treat pediatric inflammatory diseases—could be repurposed and combined with standard cancer therapies called MEK inhibitors to form a new treatment strategy for patients with high-risk JMML.
"Because chronic inflammation and immune suppression are hallmarks of many cancers, targeting this pathway may have therapeutic potential beyond JMML, including in other leukemias and solid tumors where specific inflammation signaling contributes to disease progression," said Reuben Kapur, Ph.D., director of the IU School of Medicine Herman B Wells Center for Pediatric Research and co-corresponding author of the study.
Moving forward, the research team plans to run additional preclinical tests to determine exactly which cell types are most vulnerable to this inflammatory pathway and find the best combination of drugs. They also want to evaluate whether a simple blood test measuring these specific protein levels can help doctors predict which children will benefit most from the treatment.
"The study's strong preclinical results provide a strong rationale for future translational and clinical development," Pasupuleti said.
Publication details
Santhosh Kumar Pasupuleti et al, Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia, Blood (2026). DOI: 10.1182/blood.2025032588
Journal information: Blood
Key medical concepts
Clinical categories
PediatricsOncologyChildren's health Provided by Indiana University Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Researchers identify proteins fueling rare childhood leukemia, revealing new treatment strategy (2026, June 18) retrieved 18 June 2026 from https://medicalxpress.com/news/2026-06-proteins-fueling-rare-childhood-leukemia.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.